Director dealings: Poolbeg Pharma co-founder raise stake
25th Jun 2025 14:46
(Sharecast News) - Poolbeg Pharma revealed on Wednesday that executive chair Cathal Friel had acquired 4.0m new ordinary shares in the AIM-listed biopharmaceuticals company.
Read morePoolbeg Pharma extends cash runway after raising £4.87m
23rd May 2025 12:40
(Sharecast News) - Poolbeg Pharma announced on Friday that it has conditionally raised a total of £4.865m in gross proceeds through an upsized and oversubscribed BookBuild offer, placing, and subscription.
Read morePoolbeg raises nearly £5m to progress clinical trials
20th May 2025 11:27
(Sharecast News) - Shares in biopharmaceutical group Poolbeg Pharma sank on Tuesday after the company revealed wider losses for the 2024 financial year as it raised nearly £5m in an oversubscribed placing as it progresses two key clinical trials.
Read morePoolbeg shares slide as Hookipa terminates takeover talks
21st Feb 2025 10:38
(Sharecast News) - Shares in Poolbeg Pharma were sliding on Friday, after Hookipa Pharma announced it had terminated discussions on a proposed all-share acquisition of Poolbeg, bringing an abrupt end to a deal that would have merged the two biotech companies.
Read morePoolbeg Pharma says Gilead in favour of its combination with Hookipa
10th Jan 2025 16:06
(Sharecast News) - Poolbeg Pharma updated the market on its potential combination with Hookipa Pharma on Friday, clarifying Gilead Sciences' role in the proposed concurrent fundraise.
Read morePoolbeg Pharma granted new US patent
20th Nov 2024 13:56
(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has been granted a US patent for its 'Immunomodulator I' application.
Read morePoolbeg agrees 12-month option over potential Behcet's treatment
30th Apr 2024 16:43
(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).
Read morePoolbeg Pharma to be granted US patent
20th Mar 2024 11:10
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.
Read moreDirector dealings: Poolbeg Pharma co-founder ups stake
19th Feb 2024 14:22
(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.
Read morePoolbeg upbeat on research into potential drug market
12th Feb 2024 14:37
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.
Read morePoolbeg makes promising progress with RSV programme
20th Dec 2023 13:54
(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.
Read morePoolbeg gets notice of a new Japan patent
20th Sep 2023 12:16
(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma announced the receipt of a notice of allowance from the Japanese Patent Office for its Immunomodulator I patent application on Wednesday.
Read morePoolbeg reports progress with oral vaccine development
22nd Jun 2023 14:47
(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma updated the market on its oral vaccine programme on Thursday.
Read morePoolbeg expands its focus molecule into oncology
16th Jan 2023 15:48
(Sharecast News) - Poolbeg Pharma announced the strategic expansion of 'POLB 001' into oncology on Monday.
Read morePoolbeg identifies new drug candidates with OneThree
21st Dec 2022 13:37
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.
Read more